Becton, Dickinson and Company (NYSE:BDX) Releases FY24 Earnings Guidance

Becton, Dickinson and Company (NYSE:BDX) updated its FY24 earnings guidance on Thursday. The company provided earnings per share (EPS) guidance of $12.95-13.15 for the period, compared to the consensus estimate of $12.95. The company issued revenue guidance of ~$20.1-20.3 billion, compared to the consensus revenue estimate of $20.30 billion.

Becton, Dickinson and Company Price Performance

BDX traded down $5.67 during trading on Friday, reaching $234.68. The stock had a trading volume of 1,722,353 shares, compared to its average volume of 1,291,373. The business has a 50-day moving average of $238.45 and a 200-day moving average of $240.53. Becton, Dickinson and Company has a one year low of $229.40 and a one year high of $287.32. The stock has a market cap of $67.80 billion, a PE ratio of 51.69, a PEG ratio of 1.93 and a beta of 0.45. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.64 and a current ratio of 1.41.

Becton, Dickinson and Company (NYSE:BDX) last announced its earnings results on Thursday, May 2nd. The medical instruments supplier reported $3.17 earnings per share for the quarter, beating analysts’ consensus estimates of $2.97 by $0.20. The business had revenue of $5.05 billion during the quarter, compared to analyst estimates of $5.04 billion. Becton, Dickinson and Company had a net margin of 6.76% and a return on equity of 13.90%. The company’s quarterly revenue was up 4.6% compared to the same quarter last year. During the same period in the previous year, the business earned $2.86 EPS. As a group, equities research analysts anticipate that Becton, Dickinson and Company will post 13.04 EPS for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 28th. Shareholders of record on Monday, June 10th will be issued a dividend of $0.95 per share. The ex-dividend date of this dividend is Monday, June 10th. This represents a $3.80 annualized dividend and a yield of 1.62%. Becton, Dickinson and Company’s payout ratio is currently 83.70%.

Wall Street Analyst Weigh In

Separately, Barclays increased their target price on shares of Becton, Dickinson and Company from $301.00 to $305.00 and gave the company an overweight rating in a research report on Monday, February 5th. Two analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat, Becton, Dickinson and Company has an average rating of Moderate Buy and an average price target of $280.00.

Insiders Place Their Bets

In other news, EVP Michael David Garrison sold 1,715 shares of the company’s stock in a transaction on Tuesday, April 30th. The shares were sold at an average price of $232.81, for a total value of $399,269.15. Following the completion of the transaction, the executive vice president now owns 5,381 shares in the company, valued at approximately $1,252,750.61. The sale was disclosed in a document filed with the SEC, which is available at this link. In other Becton, Dickinson and Company news, SVP Thomas J. Spoerel sold 282 shares of the company’s stock in a transaction on Thursday, March 14th. The shares were sold at an average price of $238.29, for a total transaction of $67,197.78. Following the completion of the transaction, the senior vice president now owns 2,276 shares in the company, valued at approximately $542,348.04. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Michael David Garrison sold 1,715 shares of the company’s stock in a transaction on Tuesday, April 30th. The stock was sold at an average price of $232.81, for a total transaction of $399,269.15. Following the transaction, the executive vice president now owns 5,381 shares of the company’s stock, valued at approximately $1,252,750.61. The disclosure for this sale can be found here. 0.31% of the stock is currently owned by company insiders.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.